Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
about
Preclinical evidence of rapid-onset antidepressant-like effect in Radix Polygalae extractReview of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorderGlutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatmentInflammation Models of Depression in Rodents: Relevance to Psychotropic Drug DiscoveryBeyond Monoamines-Novel Targets for Treatment-Resistant Depression: A Comprehensive ReviewChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved TherapeuticsReview of pharmacological treatment in mood disorders and future directions for drug development.Ketamine for treatment-resistant unipolar depression: current evidenceA brief history of the development of antidepressant drugs: from monoamines to glutamateEmerging targets for antidepressant therapiesNovel targets for antidepressant therapiesNew therapeutic targets for mood disordersBipolar disorder: candidate drug targets.Glutamate and its receptors in the pathophysiology and treatment of major depressive disorderChronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift.Which clinical and experimental data link temporal lobe epilepsy with depression?Brain imaging in pediatric obsessive-compulsive disorderA retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD)Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.Experimental medication treatment approaches for depression.A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy.Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disordersGlial and glutamatergic markers in depression, alcoholism, and their comorbidity.Glutamatergic modulators: the future of treating mood disorders?Stuck in a rut: rethinking depression and its treatment.Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzoleStress, depression, and neuroplasticity: a convergence of mechanisms.Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder.Novel drugs and therapeutic targets for severe mood disorders.Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.Klotho sensitivity of the neuronal excitatory amino acid transporters EAAT3 and EAAT4.Riluzole stimulates BDNF release from human plateletsRiluzole likely lacks antidepressant efficacy in ketamine non-responders.Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.Advances in the Management of Treatment-Resistant DepressionNovel glutamatergic agents for major depressive disorder and bipolar disorder.
P2860
Q21132322-7B6315AE-7F9F-4712-B39F-438DD9AE6671Q24629266-352C74FF-C34E-47D8-AB42-47FB4E9979B5Q24633004-CB95E97B-D5F3-4C2F-96B6-4EF7A5D38654Q26749497-D41A9B6E-DA98-4D0E-A3A0-92F7C2783CA5Q26782993-4CF7A547-4826-4936-BF18-B0C77E63D09AQ26782997-CF2121BE-6522-4623-B360-C0FE7F32E5C7Q26853509-BB012EC5-4794-45B8-A14E-35926E12B50BQ27004508-32013615-9115-4141-8F95-E48AB2A22595Q27028050-3E366D7E-1260-41EC-9683-133230F042FFQ28247614-9ADE7BD1-8022-4AAB-AD36-02B236C02A92Q28648254-681F40BF-CD4F-4BD1-9171-3F5CB5BE7734Q28743068-2FDBCA73-BDB5-409E-AB79-BD53781E6398Q28751133-EB2CBE35-A97D-4773-8BC3-9109F5C870B4Q30711088-46F7A855-C8C6-4A24-A9A3-789151054B00Q30906677-2AA67988-3B3E-4C92-9F3E-7E8C6F15A6E2Q31130656-ECFF1C27-86A5-47C8-B879-6A4CE3D85CC9Q33373047-FAA2F726-8430-4445-AEB7-1B3326350B17Q33463879-84781ABF-635D-41B1-B519-BBAB68DA7AD2Q33553152-CB090D12-1001-4800-9379-DB6453B54BE8Q33635577-5636C46E-2C54-45B8-83FD-4CCA8E02230FQ33658525-9F440C96-393A-4EFB-A594-3B76ECCCB89AQ33716723-968CE4C0-1522-4FA4-B1DF-F5D617F2A1B4Q33721019-D4BDD616-9C11-496F-A797-1EC77F2CE9F5Q33874459-121F9697-F86E-4145-A7C1-281BF870398EQ34204211-E14B4C50-14CE-4CC0-B4AA-98B9DF0A0EAAQ34288391-29CD5520-583E-4BB4-8D84-8E4A23729252Q34398007-0F5C258F-9B0D-40CB-BB93-84C25C4FA9C0Q34459160-D58F8910-2FA6-43EF-BBC2-AE6F7A88242DQ34551188-253DFC5A-4BF7-40E7-AA7E-6453F1ADE3DCQ34661581-ADB429CC-8851-4E8A-B763-4FA5243DBB1BQ34686632-E693B6E7-D0A2-4A49-95A8-C4E6795C4B8BQ34716110-ED463A23-6C4B-4D51-8775-80647B1DB4D7Q34732759-8E3DCD85-930B-4AD2-8527-3CB6A0E0DCDEQ34766451-0043F692-4FB3-4EF2-BFC3-EEE84624B749Q34907600-34778292-6AD3-47B6-9EC9-AFB5B82680A9Q34988697-955D5F86-1E42-43E9-96AA-E7B96E05E84AQ34989048-B3EDB630-486D-40CC-A988-33682969793FQ35001345-3332874F-B686-4403-8300-735778D81C39Q35580600-EF7A887D-EA97-4088-B3A3-52AB73B4647DQ35661119-43CCADF7-6637-4279-91DA-DF344D2BA91D
P2860
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 December 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preliminary evidence of riluzo ...... residual depressive symptoms.
@en
Preliminary evidence of riluzo ...... residual depressive symptoms.
@nl
type
label
Preliminary evidence of riluzo ...... residual depressive symptoms.
@en
Preliminary evidence of riluzo ...... residual depressive symptoms.
@nl
prefLabel
Preliminary evidence of riluzo ...... residual depressive symptoms.
@en
Preliminary evidence of riluzo ...... residual depressive symptoms.
@nl
P2093
P2860
P1476
Preliminary evidence of riluzo ...... residual depressive symptoms.
@en
P2093
Arthur A Simen
Gerard Sanacora
John H Krystal
Lisa R Fenton
Steven F Kendell
Vladimir Coric
Yael Levin
P2860
P304
P356
10.1016/J.BIOPSYCH.2006.08.037
P407
P577
2006-12-04T00:00:00Z